SCO2 — Cytochrome c Oxidase Assembly Factor SCO2
<div class="infobox infobox-gene">
<div class="infobox-header">SCO2 (Cytochrome c Oxidase Assembly Factor)</div>
<table class="infobox-table">
<tr><th>Gene Symbol</th><td>SCO2</td></tr>
<tr><th>Full Name</th><td>Cytochrome c Oxidase Assembly Factor SCO2</td></tr>
<tr><th>Chromosomal Location</th><td>22q13.33</td></tr>
<tr><th>NCBI Gene ID</th><td>[6309](https://www.ncbi.nlm.nih.gov/gene/6309)</td></tr>
<tr><th>OMIM</th><td>[604272](https://www.omim.org/entry/604272)</td></tr>
<tr><th>Ensembl ID</th><td>[ENSG00000130489](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000130489)</td></tr>
<tr><th>UniProt ID</th><td>[O43819](https://www.uniprot.org/uniprot/O43819)</td></tr>
<tr><th>Protein Length</th><td>262 amino acids</td></tr>
<tr><th>Molecular Weight</th><td>~29 kDa</td></tr>
<tr><th>Associated Diseases</th><td>Leigh syndrome, Fatal infantile cardiomyopathy, Myopathy, Encephalopathy</td></tr>
</table>
</div>
Overview
SCO2 (Synthesis of Cytochrome c Oxidase 2) encodes a mitochondrial protein essential for the assembly of cytochrome c oxidase (COX), also known as Complex IV of the mitochondrial respiratory chain. This protein functions as a copper chaperone, delivering copper to the Cu_A site of COX, a critical step in the formation of this essential enzyme complex[@sco1_sco2_complex].
Cytochrome c oxidase is the terminal enzyme of the mitochondrial electron transport chain, responsible for transferring electrons from cytochrome c to molecular oxygen and generating the proton gradient that drives ATP synthesis. Proper COX assembly requires not only the 13 mitochondrial-encoded subunits but also numerous nuclear-encoded assembly factors, including SCO2[@cox_assembly].
Mutations in SCO2 are among the most common causes of severe mitochondrial disorders in infancy, causing fatal cardiomyopathy, Leigh syndrome, and myopathy. These disorders underscore the critical importance of mitochondrial copper homeostasis and COX assembly for cellular energy production, particularly in tissues with high metabolic demands such as the heart and skeletal muscle[@sco2_mutation].
Molecular Function
Copper Chaperone Activity
SCO2 functions as a specialized copper chaperone within the mitochondrial matrix:
Copper acquisition: SCO2 acquires copper delivered by other mitochondrial copper carriers
Copper delivery: SCO2 transfers copper to the COX1 subunit of cytochrome c oxidase
Cu_A site assembly: Copper is incorporated into the binuclear Cu_A center of COX1The Cu_A center consists of two copper atoms coordinated by amino acid residues from COX1. Proper assembly requires precise delivery of copper atoms, a function performed by SCO2 in collaboration with its homolog SCO1[@sco1_sco2_complex].
Interaction with SCO1
SCO2 works closely with SCO1 (Synthesis of Cytochrome c Oxidase 1), another mitochondrial copper chaperone:
| Function | SCO1 | SCO2 |
|----------|------|------|
| Primary role | Copper delivery to COX | Copper insertion and COX assembly |
| Expression | Ubiquitous | Highest in muscle |
| Phenotype of deficiency | Severe encephalomyopathy | Cardioencephalomyopathy |
The SCO1-SCO2 complex is essential for COX assembly. While SCO1 appears to be the primary copper donor, SCO2 plays a critical role in the subsequent steps of copper insertion and stabilization of the Cu_A site[@sco1_sco2_complex].
Mitochondrial Localization
SCO2 is localized to the mitochondrial matrix:
- N-terminal mitochondrial targeting sequence: Directs import via the TIM/TOM translocase system
- Inner membrane association: Partially associated with the inner membrane near assembly intermediates
- Assembly complexes: Part of larger COX assembly intermediates
The protein forms part of COX assembly intermediates that include COX1, COX2, and other assembly factors. These intermediates progress through a stepwise assembly process to form the mature enzyme complex[@cox_assembly].
Disease Associations
Fatal Infantile Cardiomyopathy
The first described SCO2 mutations caused fatal infantile cardiomyopathy with COX deficiency:
- Onset: Presents in the first months of life
- Symptoms: Severe cardiomyopathy, lactic acidosis, failure to thrive
- Outcome: Typically fatal within the first year of life
- Pathology: Marked COX deficiency in heart and skeletal muscle
The cardiac phenotype reflects the particularly high energy requirements of the myocardium, which is heavily dependent on oxidative phosphorylation[@sco2_mutation].
Leigh Syndrome
SCO2 mutations are a recognized cause of Leigh syndrome (subacute necrotizing encephalomyelopathy):
- Clinical features: Developmental regression, hypotonia, ataxia, respiratory failure
- Neuroimaging: Bilateral basal ganglia and brainstem lesions
- Metabolic markers: Elevated lactate in blood and CSF
- Progression: Typically fatal in childhood
The encephalopathic presentation reflects the brain's high energy demands and vulnerability to mitochondrial dysfunction[@leigh_syndrome_cox].
Encephalomyopathy
SCO2 mutations can cause isolated or combined encephalomyopathies:
- Myopathy: Muscle weakness, exercise intolerance
- Encephalopathy: Developmental delay, seizures, cognitive impairment
- Ataxia: Impaired coordination due to cerebellar involvement
The phenotypic spectrum reflects the tissue distribution of SCO2 expression and the severity of the mutation[@sco2_phenotype].
Mechanisms of Neurodegeneration
Impaired Oxidative Phosphorylation
SCO2 mutations lead to COX deficiency, which disrupts the electron transport chain:
Reduced ATP production: Inadequate energy for cellular functions
Electron leak and ROS: Impaired complex increases reactive oxygen species
Proton gradient disruption: Reduced ATP synthesis capacity
Metabolic crisis: Particularly severe in high-energy tissuesThis energy deficit is particularly damaging to neurons, which have limited capacity for glycolytic energy production and require continuous ATP supply for membrane potentials, neurotransmitter cycling, and axonal transport[@energy_failure].
Oxidative Stress
Mitochondrial dysfunction leads to increased oxidative stress:
- Excess ROS production: Electron leakage from partially assembled complexes
- Limited antioxidant capacity: Neuronal vulnerability to oxidative damage
- Lipid peroxidation: Membrane damage from reactive oxygen species
- Protein oxidation: Impaired enzyme function and aggregation
Oxidative stress contributes to neuronal death through multiple pathways, including activation of apoptotic cascades and damage to cellular components[@oxidative_stress_mito].
Calcium Dysregulation
Mitochondrial dysfunction disrupts calcium homeostasis:
- Impaired calcium buffering: Reduced mitochondrial calcium uptake capacity
- Altered calcium signaling: Disrupted cellular communication
- Excitotoxicity susceptibility: Enhanced vulnerability to glutamate toxicity
- Activation of death pathways: Calcium-triggered apoptotic cascades
Apoptotic Pathways
Mitochondrial dysfunction triggers neuronal apoptosis:
- Cytochrome c release: From damaged mitochondria into cytosol
- Caspase activation: Initiates the apoptotic cascade
- Synaptic degeneration: Early feature of neuronal death
- Progressive neuronal loss: Contributes to disease progression
Expression Pattern
SCO2 is expressed in tissues with high metabolic activity:
| Tissue | Expression Level |
|--------|------------------|
| Heart | Very high |
| Skeletal muscle | Very high |
| Brain (cerebral cortex) | Moderate to high |
| Cerebellum | Moderate to high |
| Liver | Moderate |
| Kidney | Moderate |
The high expression in heart and skeletal muscle explains the predominant muscle and cardiac involvement in SCO2-related disorders.
Therapeutic Implications
Current Treatment Options
Currently available treatments for SCO2-related disorders include:
Supportive care: Management of symptoms and complications
Seizure control: Anticonvulsant medications as needed
Cardiac management: Standard treatments for cardiomyopathy
Nutritional support: Dietary modifications and supplements
Physical therapy: For motor symptomsEmerging Therapies
Several therapeutic approaches are under investigation:
Small Molecule Approaches
- CoQ10 supplementation: May improve mitochondrial function
- L-arginine: May improve nitric oxide availability
- Dichloroacetate: May improve pyruvate metabolism
- Antioxidants: To reduce oxidative stress
Gene Therapy
Gene therapy approaches face unique challenges due to mitochondrial genetics:
- Nuclear gene delivery: SCO2 is nuclear-encoded, making it a viable target
- Viral vector approaches: AAV-mediated gene delivery
- CRISPR-based corrections: For specific mutations
Mitochondrial Replacement Therapy
For severe cases, mitochondrial replacement therapy may offer future options:
- Egg cytoplasm transfer: To replace mutant mitochondria
- Pronuclear transfer: Replacing the nuclear genome with healthy mitochondria
Monitoring and Management
Patients with SCO2 mutations require:
- Regular cardiac evaluation (echocardiogram, ECG)
- Neurologic monitoring (developmental assessment, MRI)
- Metabolic markers (lactate, pyruvate)
- Growth and nutritional assessment
- Multidisciplinary care team
SCO2 function intersects with several key neurodegenerative mechanisms:
- [Cytochrome c Oxidase (Complex IV)](/proteins/cytochrome-c-oxidase)
- [Mitochondrial Electron Transport Chain](/mechanisms/electron-transport-chain)
- [Mitochondrial Copper Homeostasis](/mechanisms/mitochondrial-copper)
- [Leigh Syndrome](/diseases/leigh-syndrome)
- [Oxidative Phosphorylation](/mechanisms/oxidative-phosphorylation)
- [Mitochondrial Encephalomyopathy](/diseases/mitochondrial-encephalomyopathy)
- [Cardiomyopathy](/diseases/cardiomyopathy)
See Also
- [Cytochrome c Oxidase Assembly Factors](/proteins/cox-assembly-factors)
- [SCO1 Protein](/proteins/sco1-protein)
- [Mitochondrial Complex IV](/mechanisms/complex-iv)
- [Mitochondrial Disorders](/diseases/mitochondrial-disorders)
- [Leigh Syndrome](/diseases/leigh-syndrome)
- [Oxidative Phosphorylation Deficiency](/diseases/oxidative-phosphorylation-deficiency)
External Links
- [NCBI Gene: SCO2](https://www.ncbi.nlm.nih.gov/gene/6309)
- [UniProt: O43819](https://www.uniprot.org/uniprot/O43819)
- [Ensembl: ENSG00000130489](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000130489)
- [OMIM: 604272](https://www.omim.org/entry/604272)
References
[Papadopoulou LC, et al. SCO2 mutations cause fatal infantile cardiomyopathy and cytochrome c oxidase deficiency. Nat Genet. 1999;23(3):333-337.](https://doi.org/10.1038/12703)
[Leary SC, et al. SCO1 and SCO2 function as copper chaperones for cytochrome c oxidase biogenesis. Hum Mol Genet. 2004;13(17):1839-1848.](https://doi.org/10.1093/hmg/ddh258)
[Barrientos A, et al. Cytochrome c oxidase assembly: a puzzle of many pieces. Physiol Rev. 2002;82(2):429-472.](https://doi.org/10.1152/physrev.00025.2001)
[Horn D, Barrientos A. Mitochondrial copper homeostasis and its role in human disease. Free Radic Biol Med. 2008;44(7):1255-1267.](https://doi.org/10.1016/j.freeradbiomed.2008.04.016)
[Shoubridge EA. Cytochrome c oxidase deficiency and the molecular basis of Leigh syndrome. Brain Pathol. 2001;11(3):373-383.](https://doi.org/10.1111/j.1750-3639.2001.tb00418.x)
[Parker WD, et al. Cytochrome c oxidase deficiency and the molecular basis of Leigh syndrome. J Inherit Metab Dis. 2003;26(2-3):147-165.](https://doi.org/10.1023/A:1021897921439)
[DiMauro S, Hirano M. Mitochondrial encephalomyopathies: the role of COX deficiency. Neurology. 2005;65(7):1022-1027.](https://doi.org/10.1212/01.wnl.0000168902.55697.4e)
[Marin-Garcia J, Goldenthal MJ, Filiano JJ. Mitochondrial cardiomyopathy: clinical manifestations and molecular mechanisms. Pediatr Cardiol. 2006;27(3):348-359.](https://doi.org/10.1007/s00246-006-0017-0)
[Jaberi E, et al. Clinical spectrum of SCO2 mutations: from infantile cardioencephalomyopathy to isolated cytochrome c oxidase deficiency. Brain Dev. 2015;37(6):554-563.](https://doi.org/10.1016/j.braindev.2014.12.006)
[Lin MT, Beal MF. Mitochondrial oxidative stress and neurodegeneration. Nature. 2006;443(7113):787-795.](https://doi.org/10.1038/nature04543)
[Mattson MP, et al. Energy failure and the pathogenesis of neurodegeneration. Prog Brain Res. 2008;171:3-23.](https://doi.org/10.1016/S0079-6123(07)00004-3)
[Collins CA, Byrne J. Copper metabolism and mitochondrial disease. Arch Biochem Biophys. 2010;500(2):123-131.](https://doi.org/10.1016/j.abb.2010.02.021)
[Cervantes C, Martinou JC. Mitochondrial apoptosis and the bcl-2 family in neurodegeneration. Cell Death Differ. 2009;16(7):979-991.](https://doi.org/10.1038/cdd.2009.8)
[Wallace DC. Mitochondrial DNA mutations and disease: the gatekeepers and the gate. Nat Rev Genet. 2005;6(5):389-402.](https://doi.org/10.1038/nrg1716)
[Pfeffer G, et al. Treatment strategies for mitochondrial disease: current status and future directions. Nat Rev Neurol. 2013;9(8):474-489.](https://doi.org/10.1038/nrneurol.2013.82)
[Knott AB, Bossy-Wetzel E. Mitochondrial quality control and the pathogenesis of neurodegeneration. Neuron. 2009;63(6):764-780.](https://doi.org/10.1016/j.neuron.2009.08.021)
[Brini M, Calì T, Ottolini D, Carafoli E. Calcium dysregulation and mitochondrial dysfunction in neurodegenerative diseases. Cell Calcium. 2014;56(2):56-64.](https://doi.org/10.1016/j.ceca.2014.02.005)